Darunavir

Medical Advocates
Darunavir(Prezista/TMC-114)

Conference Archives - B

17th Annual Canadian Conf on HIV/AIDS Research
14th CROI
IDSA - 2006
HEP DART 2006
46th ICAAC

Conference Archives- C

Conferences Main Page Main New and Noteworthy Home Page

Last Update: December 04, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Pediatric data are indexed in the pediatric section

The 17th Annual Canadian Conference on HIV/AIDS
Research (CAHR 2007)

POSTER
Accuracy and Correlation of Response Predictions based on 4 Methodologies to Interpret
Darunavir Resistance in patients receiving Darunavir Containing Regimens in the POWER
Studies
J Villacian, B Winters, K Van der Borght, et al
PDF Poster

14th CROI

POSTER
Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir
of HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort
D Desbois, G Peytavin, S Matheron, et al
PDF Poster

POSTER
In-vitro Selection of HIV-1 Variants Highly Resistant to Darunavir (DRV) Using
a Mixture of HIV-1 Isolates Resistant to Multiple Protease Inhibitors (PIs)
Y Koh, T Towata, AK Goshi, et al
PDF Poster

POSTER
Binding Kinetics of PI to Wild Type and Multi-drug Resistant HIV-1 Proteases: A Mechanistic
Study of the Genetic Barrier to Resistance of Darunavir
M De Wit, I Keuleers, E Gustin, et al
PDF Poster

Defining the Upper and Lower Phenotypic Clinical Cut-offs for Darunavir/Ritonavir by the
PhenoSense Assay
E Coakley, C Chappey, J Benhamid, et al
Abstract

Prior Utilization or Resistance to Amprenavir at Screening Has Minimal Effect on the 48-Week
Response to Darunavir/r in the POWER 1, 2, and 3 Studies
G Picchio, T Vangeneugden, B Van Baelen, et al
Abstract

Darunavir/Amprenavir Cross-resistance in Clinical Samples Submitted for Phenotype/Genotype
Combination Resistance Testing
N Parkin, E Stawiski, C Chappey, E Coakley
Abstract

POSTER
TMC114/r tolerability in treatment-experienced, hepatitis B or C (HBV/HCV)
co-infected patients in POWER 1 and 3
Rachlis A, Clotet B, Baxter J, et al
PDF Poster

POSTER
Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine,
in the presence of low-dose ritonavir
Sekar V, Lefebvre E, Mariën K, et al
PDF Poster

POSTER
Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir,
in the presence of low-dose ritonavir
Sekar V, Lefebvre E, Mariën K , et al
PDF Poster

HEP DART 2006

POSTER
Prevalence of darunavir-associated mutations in samples received for routine clinical resistance testing
AR Rinehart, G Picchio; M-P de Bethune, et al
PDF Poster

POSTER
Single-center experience of darunavir (DRV) in 38 HIV-infected adults enrolled in US expanded
access program
J Gathe, Jr, K Degazon, ; C Mayberry, et al
PDF Poster

POSTER
Examination of factors influencing response to darunavir combined with low-dose ritonavir
in POWER 1, 2, and 3: Pooled 48-week analysis
J Gathe, E deJesus, R Falcon, et al
PDF Poster

POSTER
Safety and efficacy of darunavir in combination with low-dose ritonavir
P Ruane, JE Gallant, A Tennenberg, SS Guzman
PDF Poster

46th ICAAC

POSTER
Impact of use of TPV, LPV and (f)APV at screening on TMC114/r virologic response in
treatment-experienced patients in POWER 1, 2 and 3
Lefebvre E, de Béthune M-P, De Meyer S, et al
PDF Poster

POSTER
Body mass change and anthropometric-related adverse events at Week 24 in treatment
experienced HIV-infected patients receiving TMC114/r or control PIs in POWER 1, 2 and 3
Roberts A, Hoy J, Beatty G, et al
PDF Poster

POSTER
Pharmacokinetic interaction between the protease inhibitors TMC114
and lopinavir/ritonavir
Sekar V, Lefebvre E, Spinosa-Guzman S, et al
PDF Poster
POSTER
Pharmacokinetic interaction between ethinyl estradiol, norethindrone and TMC114,
a new protease inhibitor
Sekar V, Lefebvre E, Spinosa-Guzman S, et al
PDF Poster

Conferences Main Page Main New and Noteworthy Home Page

Darunavir (Prezista/TMC114) Conference Archives - B